OliX Pharmaceuticals files MedSafe application for OLX10212 Phase 2a trial
OliX Pharmaceuticals corrected its OLX10212 Phase 2a geographic atrophy trial plan, adding a New Zealand MedSafe clinical trial application filed Sept. 30, 2026, alongside the previously disclosed Australian ethics submission. Trial footprint now includes up to three sites in New Zealand and up to six in Australia.